OSRH vs CODA vs MNDO vs HCWB

For growth investors, Coda Octopus Group, Inc.

(CODA) is the stronger pick with 30. 7% revenue growth year-over-year, versus -97. 9% for HCW Biologics Inc. (HCWB). MIND C. T. I. Ltd (MNDO) offers the better valuation at 7. 6x trailing P/E, making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, MIND C.

T. I. Ltd (MNDO) is the cheapest at 7. 6x versus Coda Octopus Group, Inc. at 32. 7x.

Over the past 5 years, Coda Octopus Group, Inc.

(CODA) delivered a total return of +55. 9%, compared to -99. 9% for HCW Biologics Inc. (HCWB). Over 10 years, the gap is even starker: CODA returned +861. 1% versus HCWB's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MIND C.

T. I. Ltd (MNDO) is the lower-risk stock at 0. 05β versus OSR Holdings, Inc. 's 1. 80β — meaning OSRH is approximately 3386% more volatile than MNDO relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 2% for HCW Biologics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Coda Octopus Group, Inc.

(CODA) is pulling ahead at 30. 7% versus -97. 9% for HCW Biologics Inc. (HCWB). On earnings-per-share growth, the picture is similar: Coda Octopus Group, Inc. grew EPS 15. 6% year-over-year, compared to -1280. 5% for HCW Biologics Inc.. Over a 3-year CAGR, CODA leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coda Octopus Group, Inc.

(CODA) is the more profitable company, earning 15. 5% net margin versus -146. 8% for HCW Biologics Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -207. 6% for HCWB. At the gross margin level — before operating expenses — CODA leads at 66. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MNDO (22.

0% yield) pays a dividend. OSRH, CODA, HCWB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, MIND C.

T. I. Ltd (MNDO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 22. 0% yield). OSR Holdings, Inc. (OSRH) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNDO: +65. 7%, OSRH: -95. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OSRH (Healthcare) and CODA (Industrials) and MNDO (Technology) and HCWB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OSRH is a small-cap quality compounder stock; CODA is a small-cap high-growth stock; MNDO is a small-cap deep-value stock; HCWB is a small-cap quality compounder stock. MNDO pays a dividend while OSRH, CODA, HCWB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.